Late-onset sepsis, a serious bacterial infection afflicting premature infants, is one of the most severe complications of prematurity. Appropriate nutrition is essential to help put these infants on track for positive outcomes, but not all nutrition is created equal. With human milk–based fortifiers from Prolacta Bioscience® as part of an exclusive human milk diet (EHMD), premature infants are less likely to develop late-onset sepsis than those who are fed cow milk–based fortifiers.\textsuperscript{1-4}

Why it matters: A long-term perspective

Premature infants have up to a 26.0% chance of developing late-onset sepsis, a leading cause of mortality in neonatal intensive care units (NICUs).\textsuperscript{5} This condition is associated with a series of adverse outcomes that diminish an infant’s prospects for a healthy future:

Potential complications of late-onset sepsis\textsuperscript{6}

- Neurodevelopmental disabilities
- Longer NICU stays
- Increased ventilation use
- Predisposition to other morbidities
- Higher overall NICU costs
- Higher educational and societal costs due to disability

Achieve better outcomes with Prolacta

As hospitals seek to decrease central venous line days and drive down the incidence of late-onset sepsis in premature infants—as well as lower the overall cost of care—nutrition has a vitally important role to play. Prolacta’s human milk–based fortifiers, fed as part of an EHMD, have transformed health outcomes for tens of thousands of premature infants. Clinicians are able to get to full feeds faster\textsuperscript{7} and remove the central line sooner, making a sepsis diagnosis less likely.
What the research shows

Studies showed that hospitals effectively reduced the development of late-onset sepsis by feeding Prolacta’s well-tolerated, human milk–based products to premature infants as part of an EHMD.\(^1\)\(^3\)

**Incidence\(^1,\)\(^2\) of and evaluations\(^3\) for late-onset sepsis**

- Diet that includes cow milk–based fortifiers
- Diet that includes Prolacta’s fortifiers as part of an EHMD

<table>
<thead>
<tr>
<th>Diet Type</th>
<th>Incidence (%)</th>
<th>Evaluations (%)</th>
<th>(P) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diet that includes CMB</td>
<td>23.0%</td>
<td>30.3%</td>
<td>0.00001</td>
</tr>
<tr>
<td>Diet that includes Prolacta</td>
<td>12.5%</td>
<td>19.0%</td>
<td>0.06</td>
</tr>
</tbody>
</table>

In a separate analysis of two combined randomized trials, it was shown that for every 10% increase in the volume of milk containing cow milk–based protein (CMB) in premature infants’ diet, their risk of sepsis increased by 17.9% (95% confidence interval, 8.8% to 27.8%).\(^4\)

**For every +10% volume of milk containing CMB**

\[17.9\% \text{ increased risk of sepsis}\]

An EHMD that includes Prolacta’s products lowers the incidence of and evaluations for late-onset sepsis and puts more infants on a path to healthy growth.

---


---

Meet Prolacta Bioscience

**21 YEARS**

Founded in 1999 to advance the science of human milk and address the nutritional risks for low birth weight premature infants.

**63k+ PREMATURE INFANTS**

The growing number of lives touched by Prolacta’s products globally.

**100% HUMAN MILK–BASED PRODUCTS**

The first and only neonatal nutritional fortifiers carefully crafted exclusively from human milk.

**20+ DONOR MILK SCREENING TESTS**

Ensuring the highest standards of safety and nutritional consistency.

©2020 Prolacta Bioscience, Inc. All rights reserved. MKT-0691 Rev-0 09/2020